Pharmaceutical compositions and methods for countering chemotherapy induced cardiotoxicity
This disclosure provides methods and pharmaceutical compositions for reducing or eliminating cardiotoxicity, particularly cardiotoxicity induced by a cancer treatment or other therapy. In some cases, the methods and compositions prevent or reduce cardiotoxicity caused by anthracycline treatment. The methods provided herein often comprise administering a protective agent such as myricetin, tricetin, robinetin, ficetin, vitexin, quercetin, dihydrorobinetin, kaempferol, 7,3′,4′,5′-tetrahydroxyflavone, and myricitrin in conjunction with the administration of a cancer drug or other treatment. They may comprise administering a protective agent in combination with dexrazoxane. The compositions provided herein include co-formulations of a protective agent with a different protective agent or with a cancer treatment (e.g., anthracycline drug).
1. A pharmaceutical composition comprising an anticancer agent and a protective agent myricetin
wherein the anticancer agent is an anthracycline or salt thereof, and
wherein the molar ratio of the protective agent to the anticancer agent is from about 1:1 to about 1000:1.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is a tablet, a capsule, a liposome, or liquid.
3. The pharmaceutical composition of claim 1 , wherein the anthracycline is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, and valrubicin.
4. The pharmaceutical composition of claim 3 , wherein the anthracycline is doxorubicin or epirubicin.
5. The pharmaceutical composition of claim 1 , which is acceptable for intravenous administration.
6. The pharmaceutical composition of claim 1 , wherein the weight ratio of the protective agent to the anticancer agent is from about 1:1 to about 1000:1.
7. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition consists of the anticancer agent and the protective agent.
8. The pharmaceutical composition of claim 1 , further comprising a second protective agent.
9. The pharmaceutical composition of claim 8 , wherein the second protective agent is dexrazoxane.
10. The pharmaceutical composition of claim 1 , wherein the protective agent prevents, reduces, or eliminates cardiotoxicity induced by the anticancer agent in an individual administered with the pharmaceutical composition.
11. The pharmaceutical composition of claim 1 , wherein the molar ratio of the protective agent to the anticancer agent is from about 1:1 to about 200:1.
12. The pharmaceutical composition of claim 6 , wherein the weight ratio of the protective agent to the anticancer agent is from about 1:1 to about 200:1.